UNSPSC 51111782: Obinutuzumab

Obinutuzumab is a humanized anti-CD20 monoclonal antibody as a cancer treatment.

UNSPSC 51111782 Obinutuzumab, a Commodity code, does not map to any recent state or local procurement activity in the current dataset. The code describes a specific monoclonal antibody pharmaceutical used in oncology and hematology treatment, yet the nine recent opportunities tagged under or related to this code span unrelated categories including oxygen cylinder rental services, naloxone and drug deactivation systems, generic pharmaceuticals and OTC products, peer support worker training, clinic and wellness services, forensic drug standards, and various vendor networking and informational events—none of which involve obinutuzumab procurement or targeted cancer therapies. The source includes one networking event notice (Williamson County Purchasing Department relocation), three trade shows and vendor forums (Marion County Reverse Trade Show, Central Florida NIGP Reverse Trade Show, and Collin County Governmental Purchasers Forum), and multiple unrelated medical and pharmaceutical procurements that do not involve obinutuzumab or specialty biologics for oncology.

The code shows no active solicitation activity aligned with its pharmaceutical scope. State and local governments do procure specialty pharmaceuticals including monoclonal antibodies through group purchasing organizations (GPOs) and cooperative vehicles, but the recent-opportunities dataset contains no evidence of obinutuzumab demand in this market segment. If pursuing this code, verify whether state and local healthcare systems and Medicaid agencies in your geography are soliciting through cooperative agreements such as MMCAP or regional alliances, as these entities typically consolidate rare and specialty drug procurements; direct opportunities for individual specialty biologics at the state or local level are uncommon and more often flow through healthcare delivery networks and pharmacy benefit managers operating at scale.